Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sufentanil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 4/20 | 0.85 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.85 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.85 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sufentanil SCHEMBL41227 | 1.00 | OPRM1 (0.85) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL6057143 | 1.00 | OPRM1 (0.85) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL26728 | 0.92 | OPRM1 (1.00) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL27722103 | 0.92 | OPRM1 (1.00) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL28438312 | 0.92 | OPRM1 (0.98) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL780198 | 0.92 | OPRM1 (0.98) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL28432948 | 0.92 | OPRM1 (0.98) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL2727222 | 0.91 | OPRM1 (0.96) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Citric Acid SCHEMBL28501611 | 0.89 | OPRM1 (0.67) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL28429544 | 0.88 | OPRM1 (0.91) | OPRM1SLC22A1ABCB1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9427435-B2 | Narcotic emulsion formulations for treatment of cancer pain | TEIKOKU PHARMA USA, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150141461-A1 | Narcotic Emulsion Formulations for Treatment of Cancer Pain | TEIKOKU PHARMA USA, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8871791-B2 | Narcotic emulsion formulations for treatment of cancer pain | TEIKOKU PHARMA USA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2400838-A1 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF CANCER PAIN | Teikoku Pharma USA, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098897-A1 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF CANCER PAIN | TEIKOKU PHARMA USA, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216842-A1 | Narcotic Emulsion Formulations for Treatment of Cancer Pain | TEIKOKU PHARMA USA INC. | 2010-08-26 | — | — | US | disclosed |